Cannabinoid-2 receptor activation ameliorates hepatorenal syndrome

Authors: Eszter Trojnar, Katalin Erdelyi,Csaba Matyas, Suxian Zhao, Janos Paloczi, Partha Mukhopadhyay, Zoltan V.Varga, Gyorgy Hasko, Pal Pacher Published in Free Radical Biology and Medicine May 2020 Abstract Study rationale: Hepatorenal syndrome (HRS) is a life-threatening complication of end-stage liver disease characterized by the rapid decline of kidney function. Herein, we explored the therapeutic potential of…

Intestinal permeability–a new target for disease prevention and therapy.

Authors: Stephan C. Bischoff, Giovanni Barbara, Wim Buurman, Theo Ockhuizen, Jörg-Dieter Schulzke, et al
BMC Gastroenterology, 18 November 2014

Data are accumulating that emphasize the important role of the intestinal barrier and intestinal permeability for health and disease. However, these terms are poorly defined, their assessment is a matter of debate, and their clinical significance is not clearly established. In…